Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
26 Jun 2020
Dapagliflozin 5 mg and 10 mg FC tab
26 Jun 2020
Apalutamide 60 mg film-coated tab

Bezlotoxumab safely prevents recurrent Clostridioides difficile infection

09 Jan 2021

Bezlotoxumab is both safe and effective for the prevention of recurrent Clostridioides difficile infection (rCDI), results of a meta-analysis have shown. Moreover, bezlotoxumab may be a good therapeutic option for severe rather than mild CDI.

“CDI is one of the most common healthcare-associated infections,” the investigators said. “To reduce the rCDI, monoclonal antibodies against C. difficile toxin A (actoxumab) and toxin B (bezlotoxumab) were developed.”

A systematic review and meta-analysis was performed to assess their efficacy and safety. The investigators searched an electronic database for relevant randomized controlled trials (RCTs) assessing bezlotoxumab and/or actoxumab. Outcomes measured were the rate of rCDI and adverse events including cardiovascular and gastrointestinal events.

Four RCTs comparing antitoxin antibodies (n=1,916) with placebo (n=889) were included in the meta-analysis. Bezlotoxumab plus actoxumab significantly reduced rCDI (risk ratio [RR], 0.54, 95 percent confidence interval [CI], 0.41–0.70; p<0.001), as did bezlotoxumab monotherapy (RR, 0.62, 95 percent CI, 0.51–0.76; p<0.001), compared with placebo.

In subgroup analysis, bezlotoxumab plus actoxumab significantly prevented rCDI in patients with high-risk features, such as inpatients, those who received vancomycin treatment, and those with the BI/NAP/027 strain.

In terms of safety, no difference was noted in cardiovascular and gastrointestinal events, as well as all-cause mortality, between patients treated with bezlotoxumab and placebo.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Stephen Padilla, 31 Jan 2020
The combination of ivermectin 1% cream (IVM) and doxycycline 40-mg modified-release capsules (DMR) delivers faster responses, better response rates and greater satisfaction compared with monotherapy in patients with severe rosacea, a recent study has shown.
26 Jun 2020
Dapagliflozin 5 mg and 10 mg FC tab
26 Jun 2020
Apalutamide 60 mg film-coated tab